

Electronic supplementary material

ESM Table 3 Total cancers by insulin glargine group with insulin exposure, summarised across 147,736 person-years of follow up ($n=49,197$)

Characteristic	Data presented as	Non-glargine insulin	Non-glargine plus glargine insulin		Insulin glargine only	
	<i>n</i>	31,752	15,184		2,261	
	Person-years	92,743	51,478		3,515	
All cancers	<i>n</i> (%)	1273 (4.0)	156 (1.0)		94 (4.2)	
Model 1 ^a ($n=49,197$)	HR (95% CI)	Reference	0.53 (0.45, 0.63)	$p<0.0001$	1.28 (1.04, 1.59)	$p=0.022$
Model 2 ^b ($n= 49,197$)	HR (95% CI)	Reference	0.52 (0.44, 0.62)	$p<0.0001$	1.39 (1.11, 1.73)	$p=0.004$
Model 3 ^c ($n=35,389$)	HR (95% CI)	Reference	0.59 (0.49, 0.71)	$p<0.0001$	1.54 (1.20, 1.97)	$p=0.001$
Model 4 ^d ($n=26,420$)	HR (95% CI)	Reference	0.65 (0.53, 0.81)	$p<0.0001$	1.49 (1.09, 2.03)	$p=0.012$

^aModel 1 adjusts for prior cancer, type of diabetes, calendar year and sex, and has attained age as timescale

^bModel 2 further adjusts for metformin, sulfonylurea and other oral hypoglycaemic drugs at baseline

^cModel 3 further adjusts for diabetes duration, HbA_{1c}, diastolic BP, systolic BP and deprivation quintile

^dModel 4 further adjusts for smoking ever and BMI, but note the reduction in available sample size